Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Falkensee – page 13

1 865 clinical trials in Falkensee, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Falkensee at a glance
1 865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 865 trials in Falkensee

Open in trial search

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

A Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Laroprovstat/rosuvastatin versus rosuvastatin for lowering LDL‑C in patients with high cholesterol

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Influenza+1

Recruiting

Study of the safety and immune response of gskvx000000077430 drug combination versus standard influenza vaccine in adults 18‑64 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Soquelitinib
  • Sponsor:Corvus Pharmaceuticals Inc.

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trilaciclib dihydrochloride
  • Sponsor:Pharmacosmos A/S

Study of dienogest and drospirenone on ovulation inhibition for pregnancy prevention in healthy premenopausal women

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Dienogest
  • Sponsor:Gedeon Richter Plc.

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Falkensee

What the registry says about research in the country

01 Metabolic Disorders

Innovative research focusing on Type 2 Diabetes Mellitus management and glycemic control, evaluating new therapeutic approaches including novel compounds and established treatments.

  • Glycemic Control Studies
  • Cardiovascular Outcomes
  • Diabetes Management

Multiple trials are investigating both single and combination therapies for improving patient outcomes.

02 Cardiovascular Health

Comprehensive studies addressing atherosclerotic cardiovascular disease and cholesterol management, examining innovative treatments for reducing major adverse cardiovascular events.

  • Lipid Management
  • Cardiovascular Risk Reduction
  • Arterial Health

Research focuses on comparing effectiveness of different therapeutic approaches for cholesterol control.

03 Metabolic and Renal Health

Groundbreaking research combining treatments for chronic kidney disease and metabolic conditions, including studies on weight management and obesity-related complications.

  • Weight Management
  • Kidney Disease Progression
  • Blood Pressure Control

Trials evaluate combination therapies targeting multiple health conditions simultaneously.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.